ICOTYDE

all catalysts(0)

nothing on the calendar yet

News(2)

• J&J touts Icotyde prescriptions, but not sales, in first full quarter
  Johnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…
  endpoints · 1mo ago
• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
  Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
  biopharma_dive · 1mo ago